Determination of Anti-Adeno-Associated Virus Vector Neutralizing Antibody Titer with an In Vitro Reporter System

Adeno-associated virus (AAV) vectors are a platform of choice for in vivo gene transfer applications. However, neutralizing antibodies (NAb) to AAV can be found in humans and some animal species as a result of exposure to the wild-type virus, and high-titer NAb develop following AAV vector administration. In some conditions, anti-AAV NAb can block transduction with AAV vectors even when present at low titers, thus requiring prescreening before vector administration. Here we describe an improved in vitro, cell-based assay for the determination of NAb titer in serum or plasma samples. The assay is easy to setup and sensitive and, depending on the purpose, can be validated to support clinical development of gene therapy products based on AAV vectors.

• Publication year

  2015

• Venue

  Human Gene Therapy Methods

• Publication date

  2015-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1089/hgtb.2015.037PMID 25819687PMCID 4403012
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-term safety and efficacy of factor IX gene therapy in hemophilia B.

  2014cited by this paper
• Gene therapy enters the pharma market: The short story of a long journey

  2013cited by this paper
• Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products [excerpts]

  2013cited by this paper
• Assessment of a passive immunity mouse model to quantitatively analyze the impact of neutralizing antibodies on adeno-associated virus-mediated gene transfer.

  2013cited by this paper
• Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions.

  2013influential reference
• Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue

  2012cited by this paper
• Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics.

  2011cited by this paper
• Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.

  2011cited by this paper
• Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia

  2011cited by this paper
• Adeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents

  2011cited by this paper
• Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges

  2011cited by this paper
• Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors

  2010cited by this paper
• Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B.

  2010cited by this paper
• The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques.

  2010cited by this paper
• Safety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs

  2010cited by this paper
• Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.

  2009cited by this paper
• Safety and efficacy of gene transfer for Leber's congenital amaurosis.

  2008cited by this paper
• Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection.

  2008cited by this paper
• Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics

  2008cited by this paper
• Effect of gene therapy on visual function in Leber's congenital amaurosis.

  2008cited by this paper
• Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics.

  2007cited by this paper
• Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy.

  2006cited by this paper
• Prevalence of Neutralizing Antibodies Against Adeno-Associated Virus (AAV) Types 2, 5, and 6 in Cystic Fibrosis and Normal Populations: Implications for Gene Therapy Using AAV Vectors

  2006cited by this paper
• Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

  2006cited by this paper
• Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice.

  2006cited by this paper
• Expression of the adenovirus E4 34k oncoprotein inhibits repair of double strand breaks in the cellular genome of a 293-based inducible cell line.

  2004cited by this paper
• Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

  2002cited by this paper
• Epitope Mapping of Human Anti-Adeno-Associated Virus Type 2 Neutralizing Antibodies: Implications for Gene Therapy and Virus Structure

  2000cited by this paper
• Update on the prevalence of serum antibodies (IgG and IgM) to adeno‐associated virus (AAV)

  1999cited by this paper
• Committee for Medicinal Products for Human Use (chmp) Guideline on Immunogenicity Assessment of Biotechnology-derived Therapeutic Proteins Guideline on Immunogenicity Assessment of Biotechnology-derived Therapeutic Proteins

  year unknowncited by this paper

• Challenges in Humoral Immune Response to Adeno-Associated Viruses Determination

  2025cites this paper
• Gene therapy for age-related macular degeneration: a promising frontier in vision preservation

  2025cites this paper
• Natural history of preexisting AAV5 antibodies in adults with hemophilia B during the lead-in of the etranacogene dezaparvovec phase 3 study

  2025cites this paper
• Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors

  2025cites this paper
• Limitation of Assay Sensitivity Revealed by the Improvement of Cell-Based Assay Against Various Adeno-Associated Virus Serotypes

  2025cites this paper
• Detection of neutralizing antibody to Feline herpesvirus type 1 in cat serum.

  2025cites this paper
• Extracellular vesicles in neurological disorders: emerging roles and underlying molecular mechanisms

  2025cites this paper
• Nanotherapeutics-mediated tolerogenic induction for enabling adeno-associated virus vector gene therapy re-administration by overcoming anti-drug antibodies.

  2025cites this paper
• CoreTIA: a modular, statistically robust transduction inhibition assay for AAV neutralization

  2025cites this paper
• Completion of phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years

  2025cites this paper
• Use of CD19-targeted Immune Modulation to Eradicate AAV Neutralizing Antibodies.

  2025cites this paper
• Novel assay format for total anti-adeno-associated virus antibody detection with low capsid consumption and built-in specificity control

  2024cites this paper
• The combination of rAAV pseudo-lipid nanoparticle and triamcinolone acetonide enables multi-administration to liver

  2024cites this paper
• Comparative assessment of the transduction efficiency and safety associated with the delivery of AAV9-GFP vector via lumbar puncture to cynomolgus macaques with and without anti-AAV9 pre-existing antibodies

  2024cites this paper
• Repeated dosing of AAV-mediated liver gene therapy in juvenile rat and mouse models of Crigler-Najjar syndrome type I

  2024cites this paper
• Prevalence of Antibodies against Adeno-Associated Viruses (AAVs) in Göttingen Minipigs and Its Implications for Gene Therapy and Xenotransplantation

  2024cites this paper
• An engineered AAV targeting integrin alpha V beta 6 presents improved myotropism across species

  2024cites this paper
• Predictive power of deleterious single amino acid changes to infer on AAV2 and AAV2-13 capsids fitness

  2024cites this paper
• Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapies

  2024cites this paper
• Correlation of antigen expression with epigenetic modifications after rAAV delivery of a hyperactive human Factor IX variant in mice and rhesus macaques.

  2024cites this paper
• An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species

  2024cites this paper
• B cell focused transient immune suppression protocol for efficient AAV readministration to the liver

  2024cites this paper
• Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy

  2023influential citation
• Leveraging CRISPR-Cas9 for Accurate Detection of AAV-Neutralizing Antibodies: The AAV-HDR Method

  2023cites this paper
• Rational immunosilencing of a promiscuous T-cell epitope in the capsid of an adeno-associated virus

  2023cites this paper
• Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency)

  2023cites this paper
• Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B

  2023cites this paper
• Prednisolone and rapamycin reduce the plasma cell gene signature and may improve AAV gene therapy in cynomolgus macaques

  2023cites this paper
• Efficient removal of antibodies to adeno‐associated viruses by immunoadsorption

  2023cites this paper
• Goats with low levels of AAV antibody may serve as candidates for large animal gene therapy.

  2023cites this paper
• Enhanced sensitivity of neutralizing antibody detection for different AAV serotypes using HeLa cells with overexpressed AAVR

  2023cites this paper
• BBB opening with focused ultrasound in nonhuman primates and Parkinson’s disease patients: Targeted AAV vector delivery and PET imaging

  2023cites this paper
• Comparison of Pre-existing Anti-AAV8 Total Antibody Screening and Confirmatory Assays with a Cell-Based Neutralizing Assay in Normal Human Serum

  2023cites this paper
• Characterization of a Bioengineered AAV3B Capsid Variant with Enhanced Hepatocyte Tropism and Immune Evasion

  2023cites this paper
• Preclinical evaluation of ADVM-062, a novel intravitreal gene therapy vector for the treatment of blue cone monochromacy

  2023cites this paper
• Multiplexing AAV Serotype-Specific Neutralizing Antibodies in Preclinical Animal Models and Humans

  2023cites this paper
• Age‐stratified adeno‐associated virus serotype 3 neutralizing and total antibody prevalence in hemophilia A patients from India

  2022cites this paper
• IgG-cleavage protein allows therapeutic AAV gene delivery in passively immunized MPS IIIA mice

  2022cites this paper
• Variants of the adeno-associated virus serotype 9 with enhanced penetration of the blood–brain barrier in rodents and primates

  2022cites this paper
• Assessment of Pre-Clinical Liver Models Based on Their Ability to Predict the Liver-Tropism of Adeno-Associated Virus Vectors

  2022cites this paper
• Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders

  2022cites this paper
• Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood

  2022cites this paper
• Systemic gene therapy for methylmalonic acidemia using the novel adeno-associated viral vector 44.9

  2022cites this paper
• MSD-based assays facilitate a rapid and quantitative serostatus profiling for the presence of anti-AAV antibodies

  2022cites this paper
• Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations

  2022influential citation
• Clinical enrollment assay to detect preexisting neutralizing antibodies to AAV6 with demonstrated transgene expression in gene therapy trials

  2022cites this paper
• Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper

  2022cites this paper
• Gene Therapy

  2021cites this paper
• Humoral immune responses to AAV gene therapy in the ocular compartment

  2021cites this paper
• Low efficacy of recombinant SV40 in Ugt1a1-/- mice with severe inherited hyperbilirubinemia

  2021cites this paper
• Knockout of the CMP–Sialic Acid Transporter SLC35A1 in Human Cell Lines Increases Transduction Efficiency of Adeno-Associated Virus 9: Implications for Gene Therapy Potency Assays

  2021cites this paper
• Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia

  2021cites this paper
• A sensitive and reproducible cell-based assay via secNanoLuc to detect neutralizing antibody against adeno-associated virus vector capsid

  2021cites this paper
• Adeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog

  2021cites this paper
• Integrative approaches to enhance adeno-associated viral gene delivery.

  2021cites this paper
• Recommendations for the Development of Cell-Based Anti-Viral Vector Neutralizing Antibody Assays

  2020influential citation
• Efficacy of AAV8-hUGT1A1 with Rapamycin in neonatal, suckling, and juvenile rats to model treatment in pediatric CNs patients

  2020cites this paper
• Engineering and In Vitro Selection of a Novel AAV3B Variant with High Hepatocyte Tropism and Reduced Seroreactivity

  2020cites this paper
• Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B.

  2020cites this paper
• The End of the Beginning: The Journey to Molecular Therapies for Spinal Muscular Atrophy.

  2020cites this paper
• Modifiers of Adeno-Associated Virus-Mediated Gene Expression in Implication for Serotype-Universal Neutralizing Antibody Assay

  2020cites this paper
• IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies

  2020cites this paper
• Adeno‐associated virus‐vectored influenza vaccine elicits neutralizing and Fcγ receptor‐activating antibodies

  2020cites this paper
• Prevalence of Adeno-Associated Virus 3 Capsid Binding and Neutralizing Antibodies in Healthy and Hemophilia B Individuals from India

  2020cites this paper
• Capsid-specific removal of circulating antibodies to adeno-associated virus vectors

  2020cites this paper
• Novel Chimeric Gene Therapy Vectors Based on Adeno-Associated Virus and Four Different Mammalian Bocaviruses

  2019cites this paper
• Immune Response Mechanisms against AAV Vectors in Animal Models

  2019cites this paper
• Advancements in AAV-mediated Gene Therapy for Pompe Disease

  2019cites this paper
• Using a barcoded AAV capsid library to select for novel clinically relevant gene therapy vectors

  2019cites this paper
• Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B.

  2019cites this paper
• Molecular Engineering of Adeno-Associated Virus Capsid Improves Its Therapeutic Gene Transfer in Murine Models of Hemophilia and Retinal Degeneration

  2019cites this paper
• Engineered materials for in vivo delivery of genome-editing machinery

  2019cites this paper
• Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler–Najjar Syndrome

  2019cites this paper
• Analysis of recombinant adeno-associated viral vector shedding in sheep following intracoronary delivery

  2019cites this paper
• Threshold for Pre-existing Antibody Levels Limiting Transduction Efficiency of Systemic rAAV9 Gene Delivery: Relevance for Translation

  2019cites this paper
• Oracle or false prophet? Can we predict AAV efficacy based on preexisting antibody titers?

  2019cites this paper
• Adenovirus‐associated antibodies in UK cohort of hemophilia patients: A seroprevalence study of the presence of adenovirus‐associated virus vector–serotypes AAV5 and AAV8 neutralizing activity and antibodies in patients with hemophilia A

  2019cites this paper
• Detection of Biologically Relevant Low-Titer Neutralizing Antibodies Against Adeno-Associated Virus Require Sensitive In Vitro Assays

  2019cites this paper
• Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients.

  2019cites this paper
• Low Seroprevalence of Neutralizing Antibodies Targeting Two Clade F AAV in Humans.

  2018cites this paper
• Rapid AAV-Neutralizing Antibody Determination with a Cell-Binding Assay

  2018cites this paper
• Adeno-Associated Virus Neutralizing Antibodies in Large Animals and Their Impact on Brain Intraparenchymal Gene Transfer

  2018cites this paper
• Development of a Chemiluminescent ELISA Method for the Detection of Total Anti-Adeno Associated Virus Serotype 9 (AAV9) Antibodies

  2018cites this paper
• Considerations for Preclinical Safety Assessment of Adeno-Associated Virus Gene Therapy Products

  2018cites this paper
• Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration

  2018cites this paper
• Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction

  2018cites this paper
• Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity.

  2018cites this paper
• Low Seroprevalence of Neutralizing Antibodies Targeting Two Clade F AAV in Humans

  2018cites this paper
• Systemic AAV8-Mediated Gene Therapy Drives Whole-Body Correction of Myotubular Myopathy in Dogs.

  2017cites this paper
• Overcoming the Host Immune Response to Adeno-Associated Virus Gene Delivery Vectors: The Race Between Clearance, Tolerance, Neutralization, and Escape.

  2017cites this paper
• Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase

  2017cites this paper
• AAV Vector-Based Gene Therapy, Progress and Current Challenges

  2017cites this paper
• Autophagy determines efficiency of liver‐directed gene therapy with adeno‐associated viral vectors

  2017cites this paper
• Emerging Issues in AAV-Mediated In Vivo Gene Therapy

  2017cites this paper
• Hemophilia B Gene Therapy with a High‐Specific‐Activity Factor IX Variant

  2017cites this paper
• Strategy to detect pre-existing immunity to AAV gene therapy

  2017cites this paper
• Determination of Anti-Adeno-Associated Viral Vector Neutralizing Antibodies in Patients With Heart Failure in the Cardiovascular Foundation of Colombia (ANVIAS): Study Protocol

  2016influential citation
• Effective Depletion of Pre-existing Anti-AAV Antibodies Requires Broad Immune Targeting

  2016cites this paper
• Prevalence of neutralizing antibodies against liver-tropic adeno-associated virus serotype vectors in 100 healthy Chinese and its potential relation to body constitutions.

  2015cites this paper